opnMe News

Let´s live innovation. Want to know the latest news and trends? Read more

Subscribe to our newsletter to stay up to date with latest developments

Latest news

Order for free today: With BI-3663 and BI-0319 we release two new highly selective PTK2 PROTACs (proteolysis targeting chimeras) to opnMe.com

9 July 2019

Targeted protein degradation by exploiting the ubiquitin proteasome system has recently emerged as a new and promising modality of intervention in drug discovery. One approach to induce protein degradation is to design hetero bifunctional molecules called proteolysis-targeting chimeras – also known as PROTACs. In combination with structure-based drug design, it has allowed researchers to aim at new targets which were previously deemed “undruggable”.

With BI-3663 and BI-0319 we release two new highly selective PTK2 PROTACs

Congratulations to the winner of our 2nd opnMe poll: NMDA receptor antagonist BIII 277CL has received the majority of all votes and has been launched today. Access it now for free!
up
16

18 May 2019

Today, Boehringer Ingelheim has added its well-characterized non-covalent ATP-competitive receptor channel complex (glycine and NMDA binding sites) BIII 277CL to its molecule platform opnMe.com. High selectivity and decent PK properties make BIII 277CL a suitable tool for in vivo validation of NMDA as a therapeutic target.

The winner is NMDA

Order for free today. In connection with the 2nd International Symposium on Cathepsin C we will release three new Cathepsin C molecules on opnMe.com: BI-9740, BI-1750, and BI-2051
up
19

17 April 2019

In connection with the 2nd International Symposium on Cathepsin C we have launched today the first of three new Cathepsin C molecules on opnMe.com. These will be featured as part of a talk provided by Marc Grundl, Senior Principal Scientist, Medicinal Chemistry, Boehringer Ingelheim with the title: “Cathepsin C: a challenge for medicinal chemistry”.

BI-9740, 3-D conformation co-crystalized in the Cathepsin C protein

Collaborate now with our scientists to pursue your novel disease hypothesis for our oral BCL6 degrader
up
19

15 April 2019

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is currently seeking novel applications for its unprecedented, potent and highly selective orally bioavailable BCL6 degrader BI-1136.

Oral BCL6 degrader News Announcement

Watch the exciting success story of the launch of opnMe: Learn what issues the opnMe team had to tackle and how they overcame it…
up
18

8 April 2019

End of 2018, the opnMe core team produced a small movie which outlined the story of opnMe open innovation portal from its conception until its first successes after its launch in November 2017.

Order for free today: With BIII 890CL (crobenetine) a highly potent and selective Nav1.2 sodium channel blocker was added to opnMe.com to foster independent research and discovery
up
23

27 March 2019

The opnMe team is pleased to announce the addition of its 30th Molecule 2 Order to the Boehringer Ingelheim open innovation portal. BIII 890CL (crobenetine) is a potent, selective and highly use-dependent sodium channel blocker.

HIV Transcriptase News Announcement

With the HIV reverse transcriptase inhibitor BI-2540 we have added another molecule from our HIV pipeline to opnMe.com: Order for FREE today
up
20

18 February 2019

Now, scientists from all over world can access our molecule completely free of charge without any shipment costs to pursue further pre-clinical research independently of us.

HIV Transcriptase News Announcement

Now on opnMe.com: Boehringer Ingelheim’s strong legacy in antiviral research is shared with you! Unlock the potential of our HIV Integrase inhibitor – Order for FREE today
up
15

11 February 2019

The opnMe team is pleased to announce the addition of BI 224436 to its molecules 2 order program. Now, scientists from all over the world can access our molecule completely free of charge without any shipment costs.

HIV Integrase News Announcement

Submit your proposal for our AAV2-L1 vector to win a collaboration with Boehringer Ingelheim scientists
up
26

21 January 2019

As an expert in your field, you may be excited to learn that Boehringer Ingelheim is now seeking novel applications of its lung-specific gene therapy vector AAV2-L1 in pulmonary diseases.

AAV2-L1 for collaboration

Drug Discovery Today® features Dundee / Boehringer Ingelheim collaboration for PROTAC compound on opnMe.com
up
18

09 January 2019

Boehringer Ingelheim is to make the BET degrader compound MZ 1 available through its opnMe.com portal. The company actively supports open access in order to boost progress in biomedical and drug discovery research. MZ 1 (created at the University of Dundee) is the first external compound to be added to Boehringer Ingelheim’s’ opnMe.com portal.

read more...

Prof. Dr. Alessio Ciulli, University of Dundee. One of the pioneers in the field of PROTACs